Stocks and Investing Stocks and Investing
Wed, February 28, 2024

Andrew Fein Reiterated (ACAD) at Strong Buy and Held Target at $33 on, Feb 28th, 2024


Published on 2024-10-28 09:17:14 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Reiterated "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy and Held Target at $33 on, Feb 28th, 2024.

Andrew has made no other calls on ACAD in the last 4 months.



There are 9 other peers that have a rating on ACAD. Out of the 9 peers that are also analyzing ACAD, 3 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Reiterated at Hold and Held Target at $25 on, Monday, February 5th, 2024
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $27 on, Monday, December 18th, 2023
  • Neena Bitritto-Garg of "Deutsche Bank" Downgraded from Strong Buy to Hold and Held Target at $25 on, Thursday, December 14th, 2023


These are the ratings of the 6 analyists that currently disagree with Andrew


  • Jason Butler of "JMP Securities" Reiterated at Buy and Held Target at $42 on, Wednesday, February 7th, 2024
  • Joel Beatty of "Baird" Initiated at Buy and Held Target at $40 on, Tuesday, January 30th, 2024
  • Joseph Stringer of "Needham" Upgraded from Hold to Strong Buy and Held Target at $37 on, Wednesday, January 24th, 2024
  • Jeffrey Hung of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $40 on, Tuesday, December 19th, 2023
  • David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $38 on, Wednesday, December 13th, 2023
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $40 on, Monday, November 6th, 2023
Contributing Sources